Search
Aeon Biopharma Inc
AEONAdd to Watchlist
0.865USD
-0.015-1.70%
Market hours （ET）Quotes delayed by 15 min
10.47MMarket Cap
LossP/E TTM
More Details of Aeon Biopharma Inc Company
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.
Aeon Biopharma Inc Info
Ticker SymbolAEON
Company nameAeon Biopharma Inc
IPO dateFeb 09, 2021
CEOBancroft (Robert E)
Number of employees5
Security typeOrdinary Share
Fiscal year-endFeb 09
Address5 Park Plaza
CityIRVINE
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code92614
Phone19493546499
Websitehttps://aeonbiopharma.com/
Ticker SymbolAEON
IPO dateFeb 09, 2021
CEOBancroft (Robert E)
Company Executives of Aeon Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Jennifer Sy
Ms. Jennifer Sy
Principal Financial Officer, Chief Accounting Officer
Principal Financial Officer, Chief Accounting Officer
1.50M
+61.69%
Mr. Robert J. (Bob) Palmisano
Mr. Robert J. (Bob) Palmisano
Independent Director
Independent Director
31.46K
--
Mr. Jost Fischer
Mr. Jost Fischer
Independent Chairman of the Board
Independent Chairman of the Board
610.00
-27868.85%
Dr. Chad Oh, M.D.
Dr. Chad Oh, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Alex Wilson
Mr. Alex Wilson
Executive Vice President, Chief Legal Officer, Corporate Secretary
Executive Vice President, Chief Legal Officer, Corporate Secretary
--
--
Mr. Marc Forth
Mr. Marc Forth
Director
Director
--
-100.00%
Dr. Eric Carter, M.D., Ph.D.
Dr. Eric Carter, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Shelley Thune
Ms. Shelley Thune
Independent Director
Independent Director
--
--
Mr. Seongsoo Park
Mr. Seongsoo Park
Director
Director
--
--
Mr. Robert Bancroft
Mr. Robert Bancroft
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Jennifer Sy
Ms. Jennifer Sy
Principal Financial Officer, Chief Accounting Officer
Principal Financial Officer, Chief Accounting Officer
1.50M
+61.69%
Mr. Robert J. (Bob) Palmisano
Mr. Robert J. (Bob) Palmisano
Independent Director
Independent Director
31.46K
--
Mr. Jost Fischer
Mr. Jost Fischer
Independent Chairman of the Board
Independent Chairman of the Board
610.00
-27868.85%
Dr. Chad Oh, M.D.
Dr. Chad Oh, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Alex Wilson
Mr. Alex Wilson
Executive Vice President, Chief Legal Officer, Corporate Secretary
Executive Vice President, Chief Legal Officer, Corporate Secretary
--
--
Mr. Marc Forth
Mr. Marc Forth
Director
Director
--
-100.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Daewoong Pharma
45.43%
Bancroft (Robert E.)
12.08%
Oh (Chad M.D.)
8.29%
Wilson (Alexander Blair)
8.29%
Sy (Jennifer)
5.71%
Other
20.22%
Shareholders
Shareholders
Proportion
Daewoong Pharma
45.43%
Bancroft (Robert E.)
12.08%
Oh (Chad M.D.)
8.29%
Wilson (Alexander Blair)
8.29%
Sy (Jennifer)
5.71%
Other
20.22%
Shareholder Types
Shareholders
Proportion
Corporation
46.60%
Individual Investor
38.76%
Investment Advisor
6.76%
Hedge Fund
0.35%
Investment Advisor/Hedge Fund
0.23%
Venture Capital
0.22%
Private Equity
0.06%
Other
7.02%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
69
2.00M
7.61%
-100.66K
2025Q4
67
1.90M
16.13%
--
2025Q3
68
1.90M
16.40%
+93.23K
2025Q2
77
1.87M
15.05%
-257.13K
2025Q1
85
2.12M
3.61%
+1.74M
2024Q4
142
173.55K
77.76%
-9.58K
2024Q3
144
183.13K
72.76%
+52.30K
2024Q2
141
131.03K
75.18%
-1.02K
2024Q1
144
132.04K
79.55%
-289.14K
2023Q4
143
120.98K
87.85%
+3.34K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Daewoong Pharma
11.95M
47.23%
+11.92M
+35754.42%
Jan 21, 2026
Bancroft (Robert E.)
3.18M
12.56%
+3.00M
+1693.93%
Feb 17, 2026
Oh (Chad M.D.)
2.18M
8.61%
+1.32M
+152.62%
Mar 04, 2026
Wilson (Alexander Blair)
2.18M
8.61%
+1.32M
+152.63%
Mar 04, 2026
Sy (Jennifer)
1.50M
5.93%
+925.92K
+161.03%
Mar 04, 2026
Chernett (Jorey)
1.13M
4.46%
+1.13M
--
May 27, 2025
Dauntless Investment Group, LLC
1.13M
4.45%
--
--
Dec 15, 2025
L1 Global Manager Pty Limited
465.03K
1.84%
+340.58K
+273.69%
Mar 31, 2025
Alta Partners L.L.C
249.87K
0.99%
-336.46K
-57.38%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Jan 23, 2025
Merger
0→0
Jan 23, 2025
Merger
72→1
Jan 23, 2025
Merger
72→1
Jan 23, 2025
Merger
72→1
Date
Ex-dividend Date
Type
Ratio
Jan 23, 2025
Merger
0→0
Jan 23, 2025
Merger
72→1
Jan 23, 2025
Merger
72→1
Jan 23, 2025
Merger
72→1
